Avidity Competitors
| RNA Stock | USD 72.90 0.08 0.11% |
Avidity Biosciences vs Rhythm Pharmaceuticals Correlation
Weak diversification
The correlation between Avidity Biosciences and RYTM is 0.34 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Avidity Biosciences and RYTM in the same portfolio, assuming nothing else is changed.
Moving together with Avidity Stock
Moving against Avidity Stock
| 0.89 | GNLX | Genelux Common | PairCorr |
| 0.84 | EDIT | Editas Medicine | PairCorr |
| 0.82 | QSI | QuantumSi | PairCorr |
| 0.82 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.8 | LYRA | Lyra Therapeutics | PairCorr |
Avidity Biosciences Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Avidity Biosciences and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Avidity and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Avidity Biosciences does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Avidity Stock performing well and Avidity Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Avidity Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| JAZZ | 1.71 | 0.35 | 0.12 | (0.59) | 1.65 | 3.66 | 25.96 | |||
| MDGL | 2.14 | 0.20 | 0.08 | 0.36 | 2.04 | 7.29 | 16.78 | |||
| CAI | 2.49 | (0.48) | 0.00 | (0.48) | 0.00 | 4.14 | 19.89 | |||
| MRNA | 3.41 | 0.70 | 0.19 | 0.42 | 3.71 | 9.21 | 23.11 | |||
| ABVX | 3.20 | 0.35 | 0.07 | 4.05 | 3.38 | 6.94 | 29.38 | |||
| CYTK | 2.13 | 0.01 | 0.00 | 0.09 | 2.22 | 4.25 | 12.08 | |||
| NUVL | 2.21 | 0.19 | 0.04 | 2.83 | 2.47 | 4.10 | 17.72 | |||
| TECH | 1.77 | 0.04 | 0.04 | 0.11 | 1.71 | 3.76 | 10.34 | |||
| RYTM | 2.50 | (0.17) | 0.00 | (0.10) | 0.00 | 4.76 | 18.69 |
Cross Equities Net Income Analysis
Compare Avidity Biosciences and related stocks such as Jazz Pharmaceuticals PLC, Madrigal Pharmaceuticals, and Caris Life Sciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JAZZ | (24.8 M) | 125 M | 288.6 M | 216.3 M | 58.4 M | 329.5 M | 396.8 M | 487.8 M | 447.1 M | 523.4 M | 238.6 M | (329 M) | (224.1 M) | 414.8 M | 560.1 M | 644.1 M | 676.3 M |
| MDGL | (381 K) | (47.4 M) | (62.8 M) | (90.2 M) | (86.2 M) | (6.8 M) | (26.4 M) | (31.2 M) | (32.8 M) | (72.8 M) | (197.4 M) | (241.1 M) | (295.4 M) | (373.6 M) | (465.9 M) | (419.3 M) | (398.3 M) |
| CAI | (2.6 M) | 50.2 M | 63.5 M | 63.9 M | 60.3 M | 26.8 M | 6 M | 72.1 M | 78.6 M | 31 M | 27.7 M | (320.8 M) | (320.8 M) | (341.4 M) | (281.9 M) | (253.7 M) | (241 M) |
| MRNA | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (1.1 M) | (216.2 M) | (255.9 M) | (384.7 M) | (514 M) | (747.1 M) | 12.2 B | 8.4 B | (4.7 B) | (3.6 B) | (4.1 B) | (3.9 B) |
| ABVX | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.1 M) | (16 M) | (14.3 M) | (11.2 M) | (15.8 M) | (30.6 M) | (37.6 M) | (42.5 M) | (60.7 M) | (147.7 M) | (176.2 M) | (158.6 M) | (150.7 M) |
| CYTK | (13.1 M) | (47.9 M) | (41.7 M) | (33.7 M) | (14.6 M) | (37.5 M) | 16.5 M | (127.8 M) | (106.3 M) | (121.7 M) | (127.3 M) | (215.3 M) | (389 M) | (526.2 M) | (589.5 M) | (530.6 M) | (504 M) |
| NUVL | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (14.6 M) | (46.3 M) | (73.3 M) | (126.2 M) | (260.8 M) | (234.7 M) | (222.9 M) |
| TECH | 400 K | 112.3 M | 112.6 M | 110.9 M | 107.7 M | 104.5 M | 77.3 M | 125.3 M | 96.1 M | 229.3 M | 140.4 M | 272.1 M | 285.3 M | 168.1 M | 73.4 M | 84.4 M | 87.1 M |
| RYTM | (18.1 M) | (18.1 M) | (18.1 M) | (21.4 M) | (6.5 M) | (11.1 M) | (25.9 M) | (33.7 M) | (74.1 M) | (134.6 M) | (130.7 M) | (68 M) | (181.1 M) | (184.7 M) | (260.6 M) | (234.5 M) | (222.8 M) |
Avidity Biosciences and related stocks such as Jazz Pharmaceuticals PLC, Madrigal Pharmaceuticals, and Caris Life Sciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Avidity Biosciences financial statement analysis. It represents the amount of money remaining after all of Avidity Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Avidity Biosciences Competitive Analysis
The better you understand Avidity Biosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Avidity Biosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Avidity Biosciences' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Avidity Biosciences Competition Performance Charts
Five steps to successful analysis of Avidity Biosciences Competition
Avidity Biosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Avidity Biosciences in relation to its competition. Avidity Biosciences' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Avidity Biosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Avidity Biosciences' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Avidity Biosciences, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Avidity Biosciences position
In addition to having Avidity Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Warren Buffett Holdings Thematic Idea Now
Warren Buffett Holdings
A long-term portfolio of publicly-traded stocks on US exchanges that are owned by Warren Buffett's holding company Berkshire Hathaway. The Warren Buffett Holdings theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Warren Buffett Holdings Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Avidity Biosciences Correlation with its peers. For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avidity Biosciences. Anticipated expansion of Avidity directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Avidity Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.19) | Revenue Per Share | Quarterly Revenue Growth 4.34 | Return On Assets | Return On Equity |
Understanding Avidity Biosciences requires distinguishing between market price and book value, where the latter reflects Avidity's accounting equity. The concept of intrinsic value - what Avidity Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Avidity Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Avidity Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Avidity Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Avidity Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.